5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide manufacturers
|
| | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide Basic information |
| Product Name: | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide | | Synonyms: | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide;Org 27569;Org27569 5-Chloro-3-ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl-1H -indole-2-carboxamide;5-Chloro-3-ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl-1H-indole-2-carboxamide;1H-Indole-2-carboxamide,5-chloro-3-ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl]-;5-Chloro-3-ethyl-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-carboxamide;N-(4-(piperidin-1-yl)phenethyl)-5-chloro-3-ethyl-1H-indole-2-carboxamide;ORG 27569;ORG-27569 | | CAS: | 868273-06-7 | | MF: | C24H28ClN3O | | MW: | 409.95 | | EINECS: | 278-169-7 | | Product Categories: | Inhibitors | | Mol File: | 868273-06-7.mol | ![5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide Structure](CAS/GIF/868273-06-7.gif) |
| | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide Chemical Properties |
| Boiling point | 660.3±55.0 °C(Predicted) | | density | 1.218±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | H2O: <2mg/mL | | pka | 14.87±0.30(Predicted) | | form | powder | | color | white |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide Usage And Synthesis |
| Uses | Org 27569 is a drug that is a used in biological studies for structure-activity relationships of indole-carboxamides as CB1 receptor allosteric modulators. | | Biological Activity | Potent CB 1 receptor allosteric modulator (pEC 50 = 8.24). Significantly increases binding of the CB 1 agonist [ 3 H]CP 55.940 (pK b = 5.67) and decreases binding of the CB 1 inverse agonist [ 3 H]SR 141716A (pK b = 5.95). Inhibits CB 1 receptor antagonist efficacy in vitro (pK b = 7.57). | | in vivo | ORG 27569 (3.2 and 5.6 mg/kg, i.p.) significantly attenuates cocaine associated cue-induced reinstatement, cocaine priming-induced reinstatement, methamphetamine associated cue-induced reinstatement and methamphetamine priming-induced reinstatement in rat[1]. Org27569 (30 mg/kg, i.p.) produces CB1-independent hypophagic effects and does not affect the discriminative stimulus effects of anandamide (AEA). Org27569 (100 μg intracerebroventricularly) does not affect the pharmacologic effects of systemically administered CP55,940 compared with vehicle[3]. | | storage | Store at RT | | references | [1] price mr1, baillie gl, thomas a, stevenson la, easson m, goodwin r, mclean a, mcintosh l, goodwin g, walker g, westwood p, marrs j, thomson f, cowley p, christopoulos a, pertwee rg, ross ra. allosteric modulation of the cannabinoid cb1 receptor. mol pharmacol. 2005 nov;68(5):1484-95. epub 2005 aug 19.
[2] fay jf1, farrens dl. a key agonist-induced conformational change in the cannabinoid receptor cb1 is blocked by the allosteric ligand org 27569. j biol chem. 2012 sep 28;287(40):33873-82. epub 2012 jul 30. |
| | 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide Preparation Products And Raw materials |
|